These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 21431341)

  • 21. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
    De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Skoneczna I; Marreaud S; de Wit R; Sylvester R
    J Clin Oncol; 2009 Nov; 27(33):5634-9. PubMed ID: 19786668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
    Bamias A; Efstathiou E; Moulopoulos LA; Gika D; Hamilos G; Zorzou MP; Kakoyiannis C; Kastritis E; Bozas G; Papadimitriou C; Dimopoulos MA
    Ann Oncol; 2005 Feb; 16(2):307-13. PubMed ID: 15668289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
    Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL
    Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).
    Kim KH; Hong SJ; Han KS
    BMC Cancer; 2015 Oct; 15():812. PubMed ID: 26506914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
    De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Gil T; Marreaud S; Daugaard G; Skoneczna I; Collette S; Lorent J; de Wit R; Sylvester R
    J Clin Oncol; 2012 Jan; 30(2):191-9. PubMed ID: 22162575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer.
    Soga N; Kise H; Arima K; Sugimura Y
    Int J Clin Oncol; 2010 Aug; 15(4):376-81. PubMed ID: 20333430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
    Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
    Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.
    Naiki T; Kawai N; Hashimoto Y; Okamura T; Ando R; Yasui T; Okada A; Etani T; Tozawa K; Kohri K
    Int J Clin Oncol; 2014; 19(3):516-22. PubMed ID: 23749066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Deliveliotis C; Bafaloukos D; Kalofonos C; Xiros N; Zervas A; Mitropoulos D; Samantas E; Pectasides D; Papakostas P; Gika D; Kourousis C; Koutras A; Papadimitriou C; Bamias C; Kosmidis P; Dimopoulos MA;
    J Clin Oncol; 2004 Jan; 22(2):220-8. PubMed ID: 14665607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
    Furuiye M; Ishiwata N; Jin Y; Miyashita Y; Takano S; Yoshizawa M; Miyake S; Inase N; Yoshizawa Y
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1133-8. PubMed ID: 18633251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer.
    Yoneyama T; Imai A; Hatakeyama S; Hashimoto Y; Koie T; Ohyama C
    Int J Clin Oncol; 2015 Dec; 20(6):1179-84. PubMed ID: 26007690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
    Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
    Karapanagiotou EM; Charpidou A; Tzannou I; Dilana K; Kotteas E; Tourkantonis I; Kosmas E; Provata A; Syrigos K
    Med Oncol; 2008; 25(3):303-8. PubMed ID: 18204976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
    Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
    Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
    García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
    Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma.
    Ogawa M; Yamamoto S; Inoue T; Numao N; Yuasa T; Masuda H; Fukui I; Yonese J
    Anticancer Res; 2020 Mar; 40(3):1613-1618. PubMed ID: 32132064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.